NBW Capital LLC Sells 46 Shares of Eli Lilly and Company (NYSE:LLY)

NBW Capital LLC lowered its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 5.6% in the fourth quarter, HoldingsChannel reports. The firm owned 773 shares of the company’s stock after selling 46 shares during the period. NBW Capital LLC’s holdings in Eli Lilly and Company were worth $450,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Investors Asset Management of Georgia Inc. GA ADV grew its holdings in Eli Lilly and Company by 7.6% during the fourth quarter. Investors Asset Management of Georgia Inc. GA ADV now owns 8,894 shares of the company’s stock worth $5,165,000 after purchasing an additional 630 shares during the period. Tufton Capital Management lifted its position in Eli Lilly and Company by 430.9% during the fourth quarter. Tufton Capital Management now owns 2,336 shares of the company’s stock worth $1,362,000 after acquiring an additional 1,896 shares during the last quarter. Wright Investors Service Inc. acquired a new stake in Eli Lilly and Company during the fourth quarter worth approximately $1,680,000. Waterfront Wealth Inc. lifted its position in Eli Lilly and Company by 2.1% during the fourth quarter. Waterfront Wealth Inc. now owns 1,157 shares of the company’s stock worth $674,000 after acquiring an additional 24 shares during the last quarter. Finally, Tranquility Partners LLC lifted its position in Eli Lilly and Company by 5.2% during the fourth quarter. Tranquility Partners LLC now owns 856 shares of the company’s stock worth $499,000 after acquiring an additional 42 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have issued reports on LLY. JPMorgan Chase & Co. raised their price objective on shares of Eli Lilly and Company from $775.00 to $850.00 and gave the stock an “overweight” rating in a research report on Friday, March 15th. DZ Bank downgraded shares of Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price target for the company. in a research report on Wednesday, February 21st. Bank of America lifted their price target on shares of Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a “buy” rating in a research report on Friday, March 1st. TheStreet upgraded shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a research report on Friday, March 8th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $815.00 price target on shares of Eli Lilly and Company in a research report on Monday. Three investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $728.05.

Insiders Place Their Bets

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 78,573 shares of the business’s stock in a transaction on Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total transaction of $50,920,804.11. Following the sale, the insider now owns 99,333,810 shares of the company’s stock, valued at $64,375,262,246.70. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.13% of the company’s stock.

Eli Lilly and Company Price Performance

Shares of NYSE LLY traded down $4.42 during midday trading on Thursday, reaching $746.35. 920,828 shares of the company were exchanged, compared to its average volume of 3,056,808. The stock’s 50-day moving average price is $764.03 and its 200-day moving average price is $657.67. The stock has a market cap of $709.15 billion, a P/E ratio of 129.32, a PEG ratio of 1.63 and a beta of 0.34. Eli Lilly and Company has a one year low of $367.35 and a one year high of $800.78. The company has a quick ratio of 0.73, a current ratio of 0.94 and a debt-to-equity ratio of 1.69.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, topping analysts’ consensus estimates of $2.30 by $0.19. The firm had revenue of $9.35 billion for the quarter, compared to analysts’ expectations of $8.95 billion. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The company’s revenue was up 28.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.09 earnings per share. On average, sell-side analysts anticipate that Eli Lilly and Company will post 12.52 earnings per share for the current fiscal year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.